1 week ago
1
Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) announced on Tuesday that its experimental therapy enlicitide reached the main goals in a Phase 3 trial for adults with high cholesterol (hypercholesterolemia) who were on stable lipid-lowering therapies such as statins.
Based on topline data, the Rahway, New Jersey-headquartered
English (US) ·